Poster Session 1: Autologous Transplants
Poster Abstracts
Longhorn Hall E (Exhibit Level 1) (Gaylord Texan)
PK-Directed Intravenous Busulfan in Combination with High-Dose Melphalan and Bortezomib As Conditioning Regimen for Patients with Multiple Myeloma
Ira Braunschweig, MD, Montefiore Medical Center;
Amitabha Mazumder, MD, NYU Cancer Center;
Jason Carter, Montefiore Medical Center;
Lawrence Almanzar, Montefiore Medical Center;
Richard Elkind, PA, MS, Montefiore Medical Center;
Ramakrishna Battini, Montefiore Medical Center;
Olga Derman, MD, Montefiore Medical Center;
Noah Kornblum, Montefiore Medical Center;
Xiaonan Xue, Albert-Einstein Cancer Center;
Amit Verma, MD, Montefiore Medical Center;
Stefan Klaus Barta, MD, MS, Montefiore Medical Center
Chemosensitivity to Induction or High Dose Therapy, Pre/Post Transplant PET Negativity and Absence of Minimal Residual Disease within Mobilized Stem Cell Graft Predict Long Term Disease Free Survival in Multiple Myeloma
Sule Mine Bakanay, MD, Ankara Ataturk Training and Research Hospital;
Klara Dalva, MD, Ankara University School of Medicine;
Elif Berna Koksoy, MD, Ankara University School of Medicine;
Didem Civit, PhD, Ankara University School of Medicine;
Erol Ayyildiz, PhD, Ankara University School of Medicine;
Muhit Ozcan, MD, Ankara University School of Medicine;
Osman Ilhan, MD, Ankara University School of Medicine;
Meral Beksac, MD, Ankara University School of Medicine
Incidence and Risk Factors for the Development of Idiopathic Pneumonitis Syndrome (IPS) after Autologous Hematopoietic Cell Transplantation (AutoHCT) for Patients with Lymphoma
Yi-Bin Chen, MD, Massachusetts General Hospital;
Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute;
Brent R. Logan, PhD, Medical College of Wisconsin;
Richard T. Maziarz, MD, Oregon Health and Science University;
Xiaochun Zhu, MS, Medical College of Wisconsin;
Görgun Akpek, MD, MHS, Banner MD Anderson Cancer Center;
Hillard M. Lazarus, MD, University Hospitals Case Medical Center;
Christopher N. Bredeson, MD, MSc, The Ottawa Hospital Blood & Marrow Transplant Program;
Richard Olsson, MD, PhD, MMSc, Karolinska University Hospital;
Wael Saber, MD, MS, Medical College of Wisconsin;
Gregory A. Hale, MD, All Children's Hospital;
Franklin O. Smith, MD, University of Cincinnati Medical Center;
Mahmoud D. Aljurf, MD, MPH, King Faisal Specialist Hospital and Research Centre;
Andrew S. Artz, MD, MS, University of Chicago Hospitals;
Vincent T. Ho, MD, Dana Farber Cancer Institute;
Philip L. McCarthy, MD, Roswell Park Cancer Institute;
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin;
Kenneth R. Cooke, MD, Johns Hopkins University
Comparison of Fludarabine, Intravenous Busulfan, and Total Body Irradiation (FluBuTBI) to BEAM As Conditioning Regimens for Autologous Peripheral Blood Stem Cell Transplantation
Jocelyn De Yao, MD, Allegheny Health Network;
Entezam Sahovic, MD, Allegheny Health Network;
Santosh Sadashiv, MD, Allegheny Health Network;
Pritam Tayshetye, MD, Allegheny Health Network;
James Rossetti, DO, Allegheny Health Network;
Salman Fazal, MD, Allegheny Health Network;
Cyrus Khan, MD, Allegheny Health Network;
Gina Berteotti, Western Pennsylvania Cancer Institute;
John Lister, M.D., Western Pennsylvania Cancer Institute
Evaluation of Oxidative Stress and Genotoxicity Inpatients Undergoing Autologous Hematopoietic Stemm Cell Transplantation
Fernando Duarte, md, Federal University of Ceara;
Thayna NOGUEIRA Santos Jr., STUDENT, Federal University of ceara;
Romelia Pinheiro Gonçalves, Professor, Federal University of Ceara;
Jacques Kaufman, MD, Federal University of Ceara;
Rosangela Ribeiro, Federal Uiversity of Ceara;
Joao Paulo Leitao, Federal University of Ceara;
Daniel Mazza, MD, PhD, federal University of Ceara;
Beatriz Pitombeira, Federal University of Ceara
Efficacy of Plerixafor with Same Day Administration and Mobilization: A Retrospective Chart Review of Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Stem Cell Transplant
Nicole T. Eiseler, MD, Monter Cancer Center;
Alla Keyzner, MD, Monter Cancer Center;
Rose Roddy, RN, Monter Cancer Center;
Laura Donahue, MD, Monter Cancer Center;
Ruthee-Lu Bayer, MD, North Shore University Hospital
Impact of CD34+ Cell-Doses Given during Autologous Stem Cell Transplantation on Absolute Lymphocyte Recovery in Multiple Myeloma Patients
Laahn H Foster, MD, University of Virginia;
Gina Petroni, University of Virginia;
Paige G. Williams, University of Virginia;
Leonid Volodin, MD, University of Virginia;
Amer Beitinjaneh, MD, MPH, University of Virginia;
Mary J. Laughlin, MD, Cleveland Cord Blood Center;
Tamila L Kindwall-Keller, DO, MS, University of Virginia School of Medicine
Routine Radiographic Screening for Lymphoma before Autologous Stem Cell Transplantation (auto-SCT) Does Not Improve Relapse-Free Survival after Auto-SCT
Siddhartha Ganguly, MD, FACP, University of Kansas Medical Center;
Jennifer McRae, MD, University of Kansas Medical Center;
Jianghua He, PhD, University of Kansas Medical Center;
Clint L. Divine, MBA, MSM, The University of Kansas Cancer Center;
Sunil Abhyankar, MD, University of Kansas Medical Center;
Omar Aljitawi, University of Kansas Medical Center;
Joseph McGuirk, DO, University of Kansas Medical Center
A Comparison Between Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Thalassemia Major
Ardeshir Ghavamzadeh, M.D., Tehran University of Medical Sciences;
Amir Ali Hamidieh, MD, Tehran University of Medical Sciences;
Kamran Alimoghaddam, M.D., Tehran University of Medical Sciences;
Mohammad Jahani, hematology;oncology stemcell transplantation research center;
Seyyed Asadollah Mousavi, Tehran University of Medical Sciences;
Babak Bahar, Tehran University of Medical Sciences;
Mohammad Vaezi, Hematology,Oncology and Stem cell Transplantation Research Center;
Leyla Sharifi Aliabadi, Tehran University of Medical Sciences;
Arash Jalali, Tehran University of Medical Sciences
Patterns of Referral for, and Utilization of, Blood and Marrow Transplantation (BMT) By Race
Alyssa Clay, BS, Roswell Park Cancer Institute;
Brittany Peoples, MS, Roswell Park Cancer Institute;
Levi Ross, PhD, Roswell Park Cancer Institute;
Kirsten Moysich, PhD, Roswell Park Cancer Institute;
Yali Zhang, MPH, Roswell Park Cancer Institute;
Philip L. McCarthy, MD, Roswell Park Cancer Institute;
Theresa Hahn, PhD, Roswell Park Cancer Institute
Maximum Tolerated Dose of Lomustine in Combination with Etoposide, Cytarabine and Melphalan in a Short Conditioning Regimen in the Transplantation of Hematopoietic Stem Cells in Patients with Lymphoma
Abrahao Elias Hallack Neto, MD, PhD, Universidade Federal de Juiz de Fora;
Kelli Borges Santos, Ms, Universidade Federal de Juiz de Fora;
Luciano J. Costa, MD, PhD, Medical University of South Carolina;
Angelo Atalla, MD, Ms, Universidade Federal de Juiz de Fora;
Milton Ruiz, MD, PhD, Universidade Federal de Juiz de Fora;
Juliana Pereira, MD, PhD, Universidade de Sao Paulo
Mobilization for Autologous Stem Cell Transplantation in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma: A Single Institution Experience
Bradley M Haverkos, MD, MPH, Ohio State University Medical Center;
Susan Geyer, Ph.D., The Ohio State University;
Ali McBride, PharmD, MS, Barnes Jewish Medical Center;
Sam Penza, MD, The Ohio State University;
Steven M. Devine, MD, Ohio State Medical Center;
Leslie A Andritsos, MD, The Ohio State University;
Samantha Jaglowski, MD, Ohio State University Medical Center
Pegylated Filgrastim Is Comparable with Filgrastim As Support for Autologous Hematopoietic Stem Cell Transplantation
Juan Manuel Herrera, MD, Centro Médico Imbanco;
Jose Fernando Huertas, Centro Médico Imbanaco;
Miguel Angel Saavedra, Centro Médico Imbanaco;
Rigoberto Gomez, Centro Médico Imbanaco;
Alvaro José Guerrero, Centro Médico Imbanaco;
Jorge Enrique Duque, Centro Médico Imbanaco;
Olga Marcela Urrego, Centro Médico Imbanaco;
Rocio Del Pilar Salcedo, Centro Médico Imbanaco;
Alexander Martinez, Centro Médico Imbanaco
BEAM Vs Melphalan Based Conditioning Therapy for Second Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)
Muthu Veeraputhiran, MD, MPH, Karmanos Cancer Institute;
Tania Jain, MD, Wayne State University;
Abhinav Deol, MD, Wayne State University/Karmanos Cancer Institute;
Joseph Uberti, MD, Karmanos Cancer Institute - Wayne State Univ;
Seongho Kim, Karmanos Cancer Institute;
Gregory Dyson, Karmanos Cancer Institute;
Muneer Abidi, Wayne State University/Karmanos Cancer Center
Autologous Peripheral Blood Stem Cell Transplant Using BEAM or CBV without Cryopreservation. 82 Procedures in Patients with Relapsed Hodgkin and Non- Hodgkinxs Lymphoma
Amado Karduss, MD, Instituto de Cancerologia;
Rosendo Perez, MD, Instituto de Cancerologia;
Rodolfo Gomez, MD, Instituto de Cancerologia;
Alejo Jimenez, MD, Instituto de Cancerologia;
Pedro Reyes, MD, Instituto de Cancerologia;
Hilda Deossa, Instituto de Cancerologia;
Liliana Hurtado, Instituto de Cancerologia
Safety of Outpatient Autologous Hematopoietic Cell Transplantation (AuHCT) for Multiple Myeloma and Lymphoma
Tara M. Kroll, MD, Medical College of Wisconsin;
Arun Singavi, Medical College of Wisconsin;
William Schmidt, Medical College of Wisconsin;
Daniel Eastwood, Medical College of Wisconsin;
William Drobyski, MD, Medical College of Wisconsin;
Mary M. Horowitz, MD, MS, CIBMTR and Medical College of Wisconsin;
Jeanne Palmer, MD, Medical College of Wisconsin;
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin;
J. Douglas Rizzo, MD, MS, CIBMTR/Medical College of Wisconsin;
Wael Saber, MD, MS, Medical College of Wisconsin;
Parameswaran N. Hari, MD, MRCP, MS, CIBMTR / Medical College of Wisconsin;
Timothy Fenske, MD, Medical College of Wisconsin
A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia
Gabriel N. Mannis, MD, University of California San Francisco;
Lloyd E Damon, MD, University of California San Francisco;
Weiyun Ai, MD, PhD, University of California San Francisco;
Charalambos Andreadis, MD, MSCE, University of California San Francisco;
Karin ML Gaensler, MD, University of California San Francisco;
Lawrence D Kaplan, MD, University of California San Francisco;
Aaron C Logan, MD, PhD, University of California San Francisco;
Anuj Mahindra, MD, University of California San Francisco;
Rebecca L. Olin, MD, MSCE, University of California San Francisco;
Peter Sayre, MD, University of California San Francisco;
Catherine C Smith, MD, University of California San Francisco;
Jeffrey M Venstrom, MD, University of California San Francisco;
Jeffrey L Wolf, MD, University of California San Francisco;
Thomas G Martin, MD, University of California San Francisco
The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant
Craig Moskowitz, Memorial Sloan-Kettering Cancer Center;
Auayporn Nadamanee, City of Hope National Medical Center;
Tamas Masszi, Szent Istvan & Szent Laszlo Corporate Hospital Hematology & Stem Cell Dept;
Edward Agura, Baylor Univeristy Medical Center;
Jerzy Holowiecki, Department of Bone Marrow Transplantation & Oncohematology, Maria Sklodowska-Curie Institute of Oncology;
Muneer Abidi, Karmanos Cancer Institute;
Andy Chen, Oregon Health & Science University;
Patrick Stiff, Loyola University Medical Center;
Alessandro Gianni, Istituto Nazionale dei Tumori;
Angelo Carella, IRCCS Azienda Ospedaliera Universitaria San Martino-Ist;
Dzhelil Osmanov, Blokhin Cancer Research Center under the Russian Academy of Medical Sciences;
John Sweetenham, Huntsman Cancer Institute, University of Utah;
Anna Sureda, Addenbrooke's Hospital;
Dirk Huebner, Takeda Pharmaceuticals International Co.;
Naomi Hunder, Seattle Genetics, Inc.;
Yin Yang, Seattle Genetics, Inc.;
Jan Walewski, Maria Sklodowska-Curie Institute and Oncology Center
Characterizing Melphalan Efficacy and Toxicity in Multiple Myeloma Patients with Renal Insufficiency
Seema Patel, PharmD, University of Illinois Hospital & Health Sciences System;
Kathryn Culos, PharmD, Vanderbilt University Medical Center;
Karen Sweiss, PharmD, BCOP, University of Illinois Hospital & Health Sciences System;
Shilpa Paul, PharmD, Huntsman Cancer Institute;
Pritesh Rajni Patel, MD, University of Illinois Hospital & Health Sciences System;
Damiano Rondelli, MD, University of Illinois Hospital & Health Sciences System
Routine Prophylaxis of Pneumocystis Jirovecii Pneumonia in Recipients of Autologous Hematopoietic Stem Cell Transplantation
Kadee Raser, PA-C, University of Michigan;
Mary Lea McNulty, ANP-BC, University of Michigan;
Gregory Yanik, MD, University of Michigan;
Steven C. Goldstein, MD, University of Michigan;
John Magenau, M.D., University of Michigan;
Attaphol Pawarode, MD, University of Michigan;
Carrie L. Kitko, MD, University of Michigan;
David Hanauer, M.S., M.D., University of Michigan;
John Levine, MD, MS, University of Michigan;
Daniel R. Couriel, MD, University of Michigan
Long Term Outcomes of Autologous Hematopoietic Cell Transplant (AHCT) Following Thiotepa-Based High-Dose Therapy (HDT) in Patients with Non-Hodgkin Lymphoma (NHL)
Nilay A Shah, MD, West Virginia University;
Sherri Rauenzahn, MD, West Virginia University;
Sijin Wen, PhD, West Virginia University;
Michael Craig, MD, West Virginia University - Health Science Center;
Abraham S Kanate, MD, West Virginia University;
Mehdi Hamadani, MD, Medical College of Wisconsin;
Aaron Cumpston, PharmD, West Virginia University Hospitals
A Higher Number of CD34+ Cells Collected during Mobilization Is Independently Associated with Successful Engraftment in Autologous Stem Cell Transplant Patients
Amy Sharma, MD, North Shore University;
Ljiljiana Vasovic, MD, Montefiore Medical Center;
Xiaonan Xue, Albert-Einstein Cancer Center;
Dan Wang, M.S, Albert Einstein;
Ira Braunschweig, MD, Montefiore Medical Center;
Stefan Klaus Barta, MD, MS, Montefiore Medical Center
A Plerixafor-Based Strategy Allows Adequate Hematopoietic Stem Cell Collection in Poor Mobilizers: Results from the Canadian Special Access Program
Dawn Sheppard, BSc, MSc, MD, The Ottawa Hospital;
Christopher N. Bredeson, MD, MSc, The Ottawa Hospital Blood & Marrow Transplant Program;
Lothar Huebsch, MD, Ottawa Hospital;
David S Allan, MD, The Ottawa Hosp/Hem;
Jason Tay, MD, Msc., The University of Ottawa
Target Value-Tailored Apheresis Can Improve Prediction of Product Hematopoietic Progenitor Cells Prior to Autologous Transplantation
Dawn Sheppard, BSc, MSc, MD, The Ottawa Hospital;
Jason Tay, MD, Msc., The University of Ottawa;
Lothar Huebsch, MD, Ottawa Hospital;
Sheryl Ann McDiarmid, RN, BScN, MEd, MBA, Ottawa General Hospital;
Lisa Gilliard Martin, Canadian Blood Services;
Doug Palmer, Canadian Blood Services;
Paul Birch, Canadian Blood Services;
Anargyros Xenocostas, MD, FRCPC, London Health Sciences Centre/ U Western Ontario;
Linda Hamelin, APN, The Ottawa Hospital;
Christopher N. Bredeson, MD, MSc, The Ottawa Hospital Blood & Marrow Transplant Program
Autologous Stem Cell Mobilization with Pegfilgrastim and Planned Plerixafor Is Equally Effective and Safer As Compared with Cyclophosphamide, Pegfilgrastim and Plerixafor
Sherilyn Tuazon, MD, Thomas Jefferson University;
Manish Sharma, MD, Thomas Jefferson University;
Tingting Zhan, Ph.D., Thomas jefferson University;
Margaret Kasner, MD, Thomas Jefferson University Hospital;
Onder Alpdogan, MD, Kimmel Cancer Center, Thomas Jefferson University;
Ubaldo Martinez, MD, Kimmel Cancer Center, Thomas Jefferson University;
Dolores Grosso, DNP, Kimmel Cancer Center, Thomas Jefferson University;
Joanne Filicko-O'Hara, MD, Thomas Jefferson University Hospital;
Barbara Pro, MD, Thomas Jefferson University;
John L. Wagner, MD, Kimmel Cancer Center, Thomas Jefferson University;
Matthew Carabasi, MD, Kimmel Cancer Center, Thomas Jefferson University;
Neal Flomenberg, MD, Kimmel Cancer Center, Thomas Jefferson University;
Mark Weiss, MD, Kimmel Cancer Center, Thomas Jefferson University
Twenty Years of Autologous Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma – a Single Center Experience
Margarida Dantas Brito, MD, Instituto Português de Oncologia do Porto;
Fernando Manuel de Castro Campilho, MD, Instituto Português de Oncologia PORTO;
Rosa Branca Ferreira, MD, Instituto Português de Oncologia do Porto;
Carlos Pinho Vaz, MD, Instituto Português de Oncologia Porto;
Susana Roncon, MD, Instituto Português de Oncologia do Porto;
Antonio Campos, MD, Instituto Portugues de Oncologia Centro do Porto
